- ISIN
- US48669G1058
- CUSIP
- 48669G105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 6, 1999
Highlights
- Market Cap
- $45.84M
- Enterprise Value
- -$2.00M
- EPS (TTM)
- -A$21.69
- Total Revenue (TTM)
- A$2.52M
- Gross Profit (TTM)
- A$2.52M
- EBITDA (TTM)
- -A$45.23M
- Year Range
- $4.86 - $17.40
- Target Price
- $19.00
- ROA (TTM)
- -71.34%
- ROE (TTM)
- -109.18%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KZIA Performance Chart
Kazia Therapeutics Limited (KZIA) is up 113.2% since the beginning of the year. At $15 per share, KZIA is trading 15.6% below its 52-week high of $17. Investors who bought $1,000 worth of KZIA shares 5 years ago would now be looking at an investment worth $30.
Loading charts...
Returns By Period
Kazia Therapeutics Limited (KZIA) has returned 113.21% so far this year and 116.99% over the past 12 months.
Kazia Therapeutics Limited
- 1D
- 4.93%
- 1M
- 7.54%
- YTD
- 113.21%
- 6M
- 71.21%
- 1Y
- 116.99%
- 3Y*
- -37.95%
- 5Y*
- -50.46%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
KZIA Monthly Returns History
Based on dividend-adjusted daily data since Nov 24, 2017, KZIA's average daily return is +0.19%, while the average monthly return is +1.66%. At this rate, an investment would double in approximately 3.5 years.
Historically, 41% of months were positive and 59% were negative. The best month was Aug 2020 with a return of +109.6%, while the worst month was Dec 2024 at -65.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, KZIA closed higher 44% of trading days. The best single day was Jul 10, 2024 with a return of +248.0%, while the worst single day was Aug 1, 2022 at -47.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.95% | 44.20% | -11.95% | 83.33% | -6.30% | 14.95% | 113.21% | ||||||
| 2025 | -10.73% | -46.11% | -8.05% | -8.29% | 5.85% | 65.00% | 33.65% | -3.70% | -10.66% | 8.32% | 35.08% | -34.69% | -22.15% |
| 2024 | -31.97% | -14.68% | 21.44% | 8.07% | -22.34% | -12.08% | 63.17% | 13.49% | 1.56% | 25.61% | -4.26% | -65.76% | -59.73% |
| 2023 | 67.51% | -10.68% | 11.97% | 29.11% | -10.53% | -2.52% | -12.93% | -9.89% | 9.36% | -57.81% | 33.53% | -21.62% | -28.52% |
| 2022 | -20.43% | 0.30% | 14.73% | -16.60% | -9.95% | -27.46% | -13.57% | -57.85% | -28.10% | -24.88% | -26.95% | 1.87% | -92.70% |
| 2021 | 11.92% | 3.31% | 24.12% | -13.39% | -11.45% | 3.68% | -8.42% | 20.16% | 4.33% | -4.33% | -7.39% | -16.05% | -2.55% |
Benchmark Metrics
Kazia Therapeutics Limited has an annualized alpha of 45.00%, beta of 0.74, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 24, 2017.
- This stock participated in 209.50% of S&P 500 Index downside but only 128.55% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 45.00%
- Beta
- 0.74
- R²
- 0.01
- Upside Capture
- 128.55%
- Downside Capture
- 209.50%
Return for Risk
Risk / Return Rank
KZIA ranks 74 for risk / return — better than 74% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kazia Therapeutics Limited (KZIA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KZIA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.88 | ||
| Sortino ratioReturn per unit of downside risk | -0.29 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.32 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.73 | 2.46 | -0.73 |
| Martin ratioReturn relative to average drawdown | 3.10 | 10.92 | -7.82 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kazia Therapeutics Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kazia Therapeutics Limited was 99.58%, occurring on Apr 21, 2025. The portfolio has not yet recovered.
The current Kazia Therapeutics Limited drawdown is 98.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.58%Apr 2025 | 4y 13d | — | 5y 2moApr 2021 - now |
2020 bear market2020 | -65.41%May 2020 | 5mo 19d | 3mo 11d | 9moNov 2019 - Aug 2020 |
Rate-hike selloffLate 2018 | -64.76%Dec 2018 | 9mo 14d | 10mo 27d | 1y 8moMar 2018 - Nov 2019 |
2020 bear market2020 | -36.15%Dec 2020 | 1mo 10d | 3mo 9d | 4mo 19dNov 2020 - Apr 2021 |
2020 bear market2020 | -32.08%Nov 2020 | 2mo 4d | 9d | 2mo 13dSep 2020 - Nov 2020 |
Drawdown Indicators
| KZIA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.58% | -56.78% | -42.80% |
Max Drawdown (1Y)Largest decline over 1 year | -68.19% | -9.10% | -59.09% |
Max Drawdown (3Y)Largest decline over 3 years | -95.02% | -18.90% | -76.12% |
Max Drawdown (5Y)Largest decline over 5 years | -99.48% | -25.43% | -74.05% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.00% | -3.21% | -94.79% |
Average DrawdownAverage peak-to-trough decline | -65.55% | -10.71% | -54.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.89% | 2.04% | +35.85% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kazia Therapeutics Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kazia Therapeutics Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KZIA relative to other companies in the Biotechnology industry. Currently, KZIA has a P/S ratio of 19.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KZIA in comparison with other companies in the Biotechnology industry. Currently, KZIA has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KZIA
Add Kazia Therapeutics Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KZIA